Erin Brazel

Erin Brazel

School of Biological Sciences

Faculty of Sciences, Engineering and Technology

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.


Erin's research is focused on developing novel prevention and treatment strategies against bacterial pathogens.

During her PhD, Erin investigated the impact of zinc on the bacterial pathogen Streptococcus pneumoniae. This work provided fundamental insight into the metabolic and transcriptomic impacts of zinc stress and identified a novel drug repurposing strategy that could be exploited to restore the susceptibility of bacteria to antibiotics.

Erin continues her research on S. pneumoniae in her current role as post-doctoral researcher in the Research Centre for Infectious Diseases. By combining her microbiology and biochemistry expertise, Erin investigates pneumococcal carbohydrate metabolism, with a particular interest in the function of bacterial membrane proteins and enzymes. Her research aims to define the mechanisms underlying bacterial nutrient metabolism in the host environment and the adaptation of clinical pneumococcal isolates to specific host sites. Erin also explores the mechanisms by which these bacteria signal to and communicate with neighbouring bacteria and the host. Together, this research aims to contribute to the understanding of pneumococal biology and target these pathways as new treatment strategies against pneumococcal infections.

Erin also works closely with the R&D team at GPN vaccines Ltd in the development of a whole cell pneumococcal vaccine. This serotype-independent vaccine aims to address the major shortcomings of the currently used vaccines, including the serotype selection and high cost of manufacture. Erin brings her knowledge of S. pneumoniae biology to the team and has contributed to the invention of a range of next generation vaccine candidates. The current lead candidate, which is capable of providing improved immunogenicity and favourable properties for large-scale manufacture, will be tested in a Phase I clinical trial in late 2022.

 

 

 

 

 

Lecturer, Infection and Immunity IIIA (MICRO 3000, MICRO 3007, MICRO 3102), 2022

Practical Demonstrator, Infection and Immunity IIIA (MICRO 3000), 2016-2018

  • Committee Memberships

    Date Role Committee Institution Country
    2022 - ongoing Secretary Australian Society for Microbiology SA/NT Branch Australian Society for Microbiology Australia
    2019 - ongoing Chair Adelaide Protein Group Australian Society of Biochemistry and Molecular Biology Australia
    2019 - ongoing Representative Professional Development Standing Committee Australian Society for Microbiology Australia
    2019 - ongoing Representative Faculty of Sciences Gender Equity and Diversity The University of Adelaide Australia
    2019 - 2019 Secretary Adelaide Protein Group Australian Society of Biochemistry and Molecular Biology Australia
    2018 - ongoing Representative Australian Society for Microbiology SA/NT Branch Australian Society for Microbiology Australia
    2018 - ongoing Representative Institutional Biosafety Committee The University of Adelaide Australia
    2017 - ongoing Member Adelaide University Biosciences Network The University of Adelaide Australia
    2016 - ongoing Representative Adelaide Protein Group - Australia

Connect With Me
External Profiles